Supreme Court Maintains Telehealth Access to Abortion Pill Mifepristone
Similar Articles
Supreme Court Extends Telemedicine Access to Abortion Pill Mifepristone Through Thursday
Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill Mifepristone
Supreme Court Temporarily Blocks Nationwide Ban on Telemedicine Abortion Access
Appeals Court Blocks Mailing of Abortion Pill Mifepristone, Reinstates In-Person Requirement
Federal Appeals Court Reinstates In-Person Requirement for Mifepristone
The Supreme Court has issued an order preserving the current rules for accessing the abortion pill mifepristone, including via telehealth and mail delivery. The order stays a lower court ruling that would have imposed nationwide restrictions, allowing the drug to remain available while a legal challenge from Louisiana proceeds. The decision maintains the status quo for medication abortion, which accounts for nearly two-thirds of all abortions in the U.S.
Facts First
- The Supreme Court has maintained access to mifepristone via telehealth and mail while a lawsuit from Louisiana against the FDA proceeds.
- The order stays a May 1 ruling from the 5th U.S. Circuit Court of Appeals that would have banned mailing the drug and required in-person doctor visits.
- Medication abortions using mifepristone and misoprostol account for nearly two-thirds of U.S. abortions, with one quarter occurring via telemedicine.
- Justices Samuel Alito and Clarence Thomas publicly dissented from the court's decision to issue the order.
- The case originated from a lawsuit filed by Louisiana arguing that expanded FDA rules for mifepristone undermine the state's abortion ban.
What Happened
The Supreme Court issued an order on Thursday, approximately 30 minutes past its own set deadline, to maintain the status quo regarding medication abortion access. The order stays a May 1 ruling from the New Orleans-based U.S. 5th Circuit Court of Appeals that would have banned the mailing of mifepristone nationwide and re-instituted pre-pandemic regulations requiring in-person doctor visits. This allows mifepristone to remain available via telehealth and mail while a case brought by the state of Louisiana against the Food and Drug Administration (FDA) proceeds through lower courts. Justices Samuel Alito and Clarence Thomas issued public dissents from the court's decision.
Why this Matters to You
If you or someone you know relies on medication abortion, this decision means continued access to the most common method via telehealth, without the need for an in-person visit. For now, you can still connect with a healthcare provider online or by phone and receive a prescription for mifepristone and misoprostol for pickup at a pharmacy or via mail. This access could be crucial if you live in a state with restrictive abortion laws or limited clinic access. The legal uncertainty surrounding this case may cause anxiety for patients and providers, but the Supreme Court's action prevents an immediate, nationwide restriction that would have disrupted care for many.
What's Next
The underlying lawsuit from Louisiana challenging the FDA's rules for mifepristone will now continue in the lower courts. The Supreme Court's order is not a final ruling on the merits of the case but maintains the current access rules during the ongoing litigation. Drugmakers Danco Laboratories and GenBioPro... may continue their legal defense of the drug's availability. The case has drawn briefs from numerous states, Congress, and industry groups, indicating the legal battle is likely to continue and could eventually return to the Supreme Court for a final decision.